Viyash Scientific Ltd — earnings calls

Viyash Scientific reported Q1 FY27 revenue of Rs. 946 crores, up about 20% year-on-year, with EBITDA of Rs. 205 crores and margin expanding to 21.6%. Profit after tax rose to Rs. 79 crores, more than double the prior year, while net debt fell to Rs. 86 crores with net debt to EBITDA at 0.1x. Management discussed the signed agreement to acquire BioForLife in Italy, growth across Animal Health and Human formulation businesses, and flat API revenue attributed to customer wait-and-watch behavior on raw material pricing.

Viyash Scientific reported Q4 FY26 revenue of Rs 920 crore, up 19.1% year-on-year, with EBITDA margin expanding to 21.7% and PAT turning around to Rs 66 crore from a loss a year earlier. For the full year, revenue grew 13.8% to Rs 3,420 crore, EBITDA rose 59.6% to Rs 702 crore, and PAT increased more than 14x to Rs 225 crore. Management attributed the improvement to the integration of the merged entity, product mix optimization toward formulations and complex APIs, and merger synergies tracking ahead of initial expectations.